Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1998 1
2000 2
2002 2
2003 2
2006 1
2007 2
2008 4
2009 5
2010 2
2011 3
2012 2
2013 2
2014 1
2015 1
2016 2
2017 2
2018 7
2019 7
2020 8
2021 5
2022 6
2023 7
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean homa pm (1 results)?
The More Recent History of Hemophilia Treatment.
Franchini M, Mannucci PM. Franchini M, et al. Semin Thromb Hemost. 2022 Nov;48(8):904-910. doi: 10.1055/s-0042-1756188. Epub 2022 Sep 15. Semin Thromb Hemost. 2022. PMID: 36108649 Free article. Review.
Another section is focused on the current state of gene therapy, which is a promising definitive cure for severe hemophilia A and B....
Another section is focused on the current state of gene therapy, which is a promising definitive cure for severe hemophilia A …
Hemophilia treatment innovation: 50 years of progress and more to come.
Mannucci PM. Mannucci PM. J Thromb Haemost. 2023 Mar;21(3):403-412. doi: 10.1016/j.jtha.2022.12.029. J Thromb Haemost. 2023. PMID: 36858789 Free article. Review.
Subsequently, the unmet needs pertaining to therapeutic adherence and thus to prophylaxis effectiveness led to the availability of factor VIII and IX products with an extended plasma half-life as well as to emicizumab, the first nonfactor medicine for subcutaneous administration …
Subsequently, the unmet needs pertaining to therapeutic adherence and thus to prophylaxis effectiveness led to the availability of factor VI …
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jiménez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Négrier C, et al. Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. Lancet Haematol. 2023. PMID: 36716761 Clinical Trial.
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs UJ, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, Möhnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer FJ, Werwitzke S, Klamroth R. Tiede A, et al. Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16. Lancet Haematol. 2023. PMID: 37858328 Clinical Trial.
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.
Pfrepper C, Klamroth R, Oldenburg J, Holstein K, Eichler H, Hart C, Moehnle P, Schilling K, Trautmann-Grill K, Alrifai M, Ay C, Miesbach W, Knoebl P, Tiede A. Pfrepper C, et al. Hamostaseologie. 2024 Dec;44(6):466-471. doi: 10.1055/a-2197-9738. Epub 2023 Dec 4. Hamostaseologie. 2024. PMID: 38049124 Free article.
BACKGROUND: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII (FVIII). ...
BACKGROUND: Acquired hemophilia A (AHA) is a severe bleeding disorder caused by autoantibodies against coagulation factor VIII …
Acquired haemophilia and PM-Scl antibodies.
Beyne-Rauzy O, Fortenfant F, Adoue D. Beyne-Rauzy O, et al. Rheumatology (Oxford). 2000 Aug;39(8):927-8. doi: 10.1093/rheumatology/39.8.927. Rheumatology (Oxford). 2000. PMID: 10952757 No abstract available.
Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates.
Nakajima Y, Osuna M, Mizumachi K, Shimonishi N, Furukawa S, Ogiwara K, Nogami K. Nakajima Y, et al. Res Pract Thromb Haemost. 2024 Jun 18;8(4):102479. doi: 10.1016/j.rpth.2024.102479. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39114481 Free PMC article.
BACKGROUND: Venous thromboembolic events have been reported in persons with hemophilia A who received emicizumab and activated prothrombin complex concentrate (APCC) concomitantly, but the relevant mechanism(s) remains unclear. ...CONCLUSION: FII and FIXa in APCCs w …
BACKGROUND: Venous thromboembolic events have been reported in persons with hemophilia A who received emicizumab and activated …
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review.
Punt MC, Waning ML, Mauser-Bunschoten EP, Kruip MJHA, Eikenboom J, Nieuwenhuizen L, Makelburg ABU, Driessens MHE, Duvekot JJ, Peters M, Middeldorp JM, Bloemenkamp KWM, Schutgens REG, Lely AT, van Galen KPM. Punt MC, et al. Blood Rev. 2021 Sep;49:100826. doi: 10.1016/j.blre.2021.100826. Epub 2021 Mar 20. Blood Rev. 2021. PMID: 33775466 Free article.
73 results